Glivec / Gleevec (Imatinib) – Novartis’ many crystalline forms


I posted a note earlier in Spicy IP Tidbits about Novartis’ alpha crystalline Glivec (imatinib) patent which has recently come to light. This application was filed back in 2004, before the changes to Indian patent law, and the subsequent (and ongoing) fight with the IPAB, etc.(Click here for a list of earlier posts about Novartis and Glivec on SpicyIP.) For those who aren’t aware, Novartis has other patents covering imatinib in similar ways. Take for example, WO 2007023182 for Delta…


Read More »
Uncategorized

SpicyIP Events – NIIPM Courses – January 2008


1. The National Institute of Intellectual Property Management (NIIPM) has organized a Training course on patents at its headquarters in Nagpur, India for 16 and 17 January 2008. NIIPM stated that the course has come about because: “it is observed that the patent applications filed by the Indian inventors and companies, are less as compared to foreign applicants. Hence many Indian inventions are not patented and thus remain unprotected and through ignorance of patent law, many inventors jeopardize the chance…


Read More »

SpicyIP Tidbits – No Magnum, More Glivec, Namenda Para IVs, & bio-trade in Namibia


1. After 15 years, High Court rules, “No use of ‘Magnum’ as trademark”13 Jan 2008, Times of India Allowing a petition filed by cigarette giant ITC, a division bench of Justices S Radhakrishnan and Anoop Mohta recently quashed an order allowing rival GTC Industries to register a trademark for ‘Magnum’. “We are of the view that the word ‘magnum’ is of common usage and purely descriptive,” said the judges. “It can serve as an indication of character or quality or…


Read More »
Uncategorized

An Indian DMCA?


We recently posted a note on Spicy tidbits about the increase in copyright notices to Indian ISPs. I picked this up and posted over at IP Think Tank about the increased pressure on ISPs around the world. One suggestion (by Will), was that the world should take note of the Digital Millenium Copyright Act (DMCA) in the United States and follow suit. Canada are about to do this (though with some controversy). For those who don’t know the detail, it…


Read More »

SpicyIP Events


1. IP Business Congress 25-27 June 2008, AmsterdamPresented by iam-magazine and Ocean Tomo. From the conference website: The IP Business Congress 2008 is an event unlike any other in the IP calendar. Bringing together IP leaders from around the world, the Congress will demonstrate why more and more people describe intellectual property as the pivotal business asset of the 21st century. No one who has an interest in the management and monetisation of IP rights will want to miss this…


Read More »

SpicyIP Tidbits


1. Natco (unsurprisingly) considering challenge to HC ruling on GlivecThanks to livemint for this article confirming that Natco is considering a challenge to the High Court ruling that India’s Intellectual Property Appeals Board may hear it’s appeal without a technical member.For more on this dispute, click here, here and here. 2. A nice piece on music copyright infringement in India Thanks to Ben from musiclawupdates for pointing out this Hindustan times article. The article sets out the usual arguments as…


Read More »

Indian Ingenuity in the Pharma industry – not just generics


Eli Lilly and Glenmark announced last week a deal in which Lilly will license from Glenmark the rights to a new set of molecules (a portfolio of TRPV1 antagonist molecules, including a clinical compound, GRC 6211.) The world has for some time been well aware (and impressed) with the performance of India’s top ‘generic’ companies. In an interesting example of taking a generic IP Strategy to the next level, Lupin entered into two recent IP portfolio sales to Servier earlier…


Read More »

Spicy Tidbits & Events


Prizes instead of patents for pharmaceuticals Senator Sanders introduced the Medical Innovation Prize Fund Act of 2007 into the US Congress. In essence the idea is to provide a large fund of money to provide government backed incentives (‘prizes’) to help direct pharmaceutical research into needed areas. The aim is to separate innovation from the proce of products. The prizes will be substituted for patent monopolies (though patents would still play a role in who gets each prize). The team…


Read More »

Big Mac’s new India strategy – what about IP?


The Economic Times recently reported on McDonalds’ recent redirection away from children and towards teenagers, adults and even the elderly. This calls for a major reassessment of the branding and IP Strategy. We’re all aware of the relatively recent “I’m lovin it” brand – but what else could McDonalds do from an IP perspective to make the most of the refocus? Interestingly, the refocus hasn’t yet hit McDonads’ India website yet – when I recently looked at it, Ronald McDonald…


Read More »

Indian Pharmaceutical Lifecycle Management – an oxymoron?


India’s section 3(d) poses some interesting problems for innovator companies seeking to get the best return on investment in India (read ‘longest period of monopoly’). Is that the end of the story for Lifecycle Management in India, though? First up – for those who think that “Lifecycle Management” is a dirty word (phrase), consider (a) the number of ‘innovators’ with generic subsidiaries, or who have entered authorised generic deals, and (b) the enormous and successful new chemical entity programs by…


Read More »